• More Than 20,000 Takeda Employees Across 80 Countries and Regions Voted to Select the FY2025 New Awardees: International Medical Corps (IMC), the Society of Critical Care Medicine (SCCM), the United Nations Office for Project Services (UNOPS) Bangladesh, and Vitamin Angels
• Takeda’s Four New Collaborations—A Commitment of JPY 4.6 Billion (Approx. USD 32.1 Million)—Boost the Total Global CSR Program Contributions to JPY 33.4 Billion (Approx. USD 238.7 Million) Across 38 Diverse Collaborations Worldwide and Extend Our Reach to an Additional 26.6 Million Direct Beneficiaries
• Takeda’s Global CSR Program Expects to Reach 53.7 Million People in 94 Countries by 2030

OSAKA, Japan & CAMBRIDGE, Mass. -- (BUSINESS WIRE) --

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to building climate-resilient health systems in low- and middle-income countries around the world. Amid rising temperatures and extreme weather events, Takeda recognizes an urgent need to ensure that healthcare remains resilient and accessible, particularly in regions most susceptible to the impacts of climate change. Climate action is critically underfunded, receiving less than 2% of philanthropic funding.*1 Through its FY2025 collaborations, Takeda is deepening its focus on supporting the world’s most vulnerable communities, addressing the greatest threats to health systems worldwide. This renewed focus reflects Takeda’s mission to continue to improve health outcomes and enhance the climate resilience of health systems as the global aid landscape keeps evolving.

Since its launch in 2016, Takeda’s Global CSR Program has reached more than 21.1 million direct beneficiaries across 93 countries. This includes improving healthcare service delivery for 15.3 million people, empowering 5.5 million community members through health education, and providing capacity-building support to over 129,000 health workforce members, while enhancing support across the key building blocks of health system strengthening.

By 2030, the four new collaborations are anticipated to extend Takeda’s impact to 53.7 million people across 94 countries, raising the total contributions from Takeda’s Global CSR Program to over JPY 33.4 billion (approx. USD 238.7 million) across 38 significant collaborations. These new partners were selected by more than 20,000 Takeda employees across 80 countries and regions through a company-wide vote, highlighting the company’s commitment to a collaborative and inclusive approach to its global corporate giving initiative.

“I’m incredibly proud that over 20,000 Takeda colleagues shaped this year’s Global CSR efforts, demonstrating our shared values and commitment to making a difference. This employee-driven program reflects who we are and ensures our corporate giving aligns with what matters to our people,” said Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer at Takeda. “This year, we focus on building climate-resilient health systems by partnering with organizations rooted in local communities. Together, we’ll address climate-related health risks, scale innovative solutions, and strengthen long-term resilience. These efforts will not only improve health outcomes but also inspire broader change in regions most vulnerable to climate impacts.”

Takeda’s commitments to these new awardees in FY2025 include:

• JPY 906 million (approx. USD 6.3 million) to International Medical Corps (IMC) Enhancing health and delivering better outcomes for 5.6 million people by improving access to medicine through climate-resilient supply chain innovation in Kenya and Somalia.
• JPY 1,500 million (approx. USD 10.4 million) to the Society of Critical Care Medicine (SCCM) Protecting the lives of 396,000 patients by ensuring uninterrupted access to lifesaving healthcare services through climate-resilient energy innovation at core hospitals in The Gambia, Liberia, and Sierra Leone
• JPY 1,024 million (approx. USD 7.1 million) to the United Nations Office for Project Services (UNOPS) Bangladesh Safeguarding over 7.3 million frontline health workers and patients from serious infection risks due to hazardous waste exposure by establishing climate-resilient waste systems in Bangladesh
• JPY 1,212 million (approx. USD 8.4 million) to Vitamin Angels Preventing child deaths and improving health outcomes for 12.1 million people by scaling evidence-based nutrition interventions nationwide in Indonesia

The new awardees shared:

• “Thanks to Takeda’s extremely generous support, we will be able to help Kenya’s and Somalia’s healthcare systems overcome significant supply-chain challenges,” said Nancy Aossey, President and CEO of IMC. “This award will enable us to deploy the Pharmaceutical Information Management System (PIMS) across 1,200 healthcare facilities and provide millions of mothers and children with lifesaving care. We also will be able to train thousands of healthcare workers, ensuring long-term impact.”
• “Reliable energy is crucial for healthcare,” said Jose L. Pascual, President of SCCM. “By providing renewable, resilient, and sustainable energy infrastructure to hospitals in The Gambia, Sierra Leone, and Liberia, SCCM is not just powering hospitals, but saving lives, empowering healthcare workers, and building a healthier, more sustainable future for generations to come.”
• “Our partnership with Takeda is a powerful example of what we can achieve when we join forces to tackle complex challenges.” said Sanjay Mathur, Regional Director for Asia and the Pacific Region at UNOPS. “Together, we’re helping build safer, more climate-resilient healthcare systems in Bangladesh addressing medical waste head-on while strengthening local capacity. We’re proud to continue our collaboration with Takeda across the region, showing how private sector partnerships can drive real, lasting impact in public health.”
• “Climate shocks have grave consequences on the health and well-being of the most nutritionally vulnerable groups in Indonesia, pregnant women, infants, and young children.” said Ana Céspedes, CEO, Vitamin Angels “With the generous support of Takeda, Vitamin Angels will train 1.2 million healthcare workers and deliver effective nutrition solutions to 12.1 million pregnant mothers and children. These efforts will have a profound impact and lead to a stronger and more climate-responsive health system in Indonesia.”

Takeda’s contributions to global health through its Global CSR Program have centered around the following areas, informed by WHO’s Health System Strengthening Building Blocks:

• Accelerating Service Delivery and Access to Essential Medicines: Improved accessibility, coverage and quality of service delivery (e.g., screening, referrals and follow ups) for more than 15.3 million people; empowered more than 5.5 million community members with targeted health education on topics such as nutrition, water, sanitation, hygiene, and sexual and reproductive health; and refurbished or built over 2,700 health facilities.
• Empowering the Health Workforce: Enhanced the knowledge, skills, motivation and deployment of the health workforce and stakeholders by providing training to over 129,000 individuals, including qualified health professionals, community health workers, government officials, health supply chain managers, and health information system administrators.
• Advancing Health Information Systems: Developed, enhanced, or implemented 274 digital solutions, platforms, or tools to support data-informed health planning and health decision-making.

Specific results at the intersection of health and climate across these focus areas include:

• 4.3 million people reached through healthcare services addressing climate-related health risks.
• 1.6 million community members educated on climate mitigation and adaptation.
• 194 health facilities refurbished or built to support climate-resilient infrastructure.
• 22,899 health workforce members trained in climate-resilient healthcare services.
• 25 digital solutions, platforms, or tools developed, enhanced, or implemented to support climate-resilient healthcare services.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Exchange Rates

In this press release, certain amounts presented in Japanese yen have been translated to U.S. dollars solely for the convenience of the reader. Except where otherwise noted, these convenience translations have been made at an exchange rate of 1USD = 144.17 JPY, the Noon Buying Rate certified by the Federal Reserve Bank of New York on June 30, 2025. The rate and methodologies used for these convenience translations differ from the currency exchange rates and translation methodologies under IFRS used for the preparation of Takeda’s consolidated financial statements. These translations should not be construed as a representation that the Japanese yen amounts could be converted into U.S. dollars at this or any other rate.

*1: climatework GLOBAL INTELLIGENCE, November 2023.